Aanbestedingen: CR2O B.V.
5 gearchiveerde aanbestedingen
CR2O B.V. is van oudsher een koper van gezondheidszorg en maatschappelijk werk, gezondheidsdiensten en IT-diensten: adviezen, softwareontwikkeling, internet en ondersteuning.
Recente aankopen door CR2O B.V.
2021-03-18
Fill and Finish Vendor of C1 Expressed Monoclonal Antibodies (mAbs) for Clinical Phase I Study (MANCO) (CR2O B.V.)
The MANCO consortium is developing monoclonal antibodies against 2019-nCoV. As one of the consortium partners CR2O BV will coordinate the phase I clinical trial and is in charge for the selection of the vendor responsible for the fill and finish process of the mAbs according to cGMP. Bekijk de aanbesteding »
The MANCO consortium is developing monoclonal antibodies against 2019-nCoV. As one of the consortium partners CR2O BV will coordinate the phase I clinical trial and is in charge for the selection of the vendor responsible for the fill and finish process of the mAbs according to cGMP. Bekijk de aanbesteding »
2021-03-11
Medical Monitoring Service for Clinical Phase I Study (MANCO) (CR2O B.V.)
The MANCO consortium is developing a monoclonal antibody against 2019-nCoV. CR2O is a partner within this consortium and responsible for the clinical operations. For the clinical Phase I study we require a medical monitoring provider. Bekijk de aanbesteding »
The MANCO consortium is developing a monoclonal antibody against 2019-nCoV. CR2O is a partner within this consortium and responsible for the clinical operations. For the clinical Phase I study we require a medical monitoring provider. Bekijk de aanbesteding »
2021-03-09
GMP Manufacturing of Monoclonal Antibodies (IMP) Using the C1 Expression System (Myceliophthora thermophila fungus)... (CR2O B.V.)
The MANCO consortium is developing monoclonal antibodies against 2019-nCoV. CR2O is a partner within this consortium and responsible for the clinical operations. For pre-clinical and clinical Phase I study we require a GMP manufacturing company for the production of monoclonal antibodies (IMP) using the C1 expression system (Myceliophthora thermophila fungus). Bekijk de aanbesteding »
The MANCO consortium is developing monoclonal antibodies against 2019-nCoV. CR2O is a partner within this consortium and responsible for the clinical operations. For pre-clinical and clinical Phase I study we require a GMP manufacturing company for the production of monoclonal antibodies (IMP) using the C1 expression system (Myceliophthora thermophila fungus). Bekijk de aanbesteding »
2020-06-11
GMP Manufacturing of Monoclonal Antibodies (IMP) using Transient and Stable CHO Expression Systems for Pre-clinical... (CR2O B.V.)
The MANCO consortium is developing monoclonal antibodies against 2019-nCoV. CR2O is a partner within this consortium and responsible for the clinical operations. For pre-clinical and clinical Phase I study we require a GMP manufacturing company for the production of monoclonal antibodies (IMP) using transient and stable CHO expression systems. Bekijk de aanbesteding »
The MANCO consortium is developing monoclonal antibodies against 2019-nCoV. CR2O is a partner within this consortium and responsible for the clinical operations. For pre-clinical and clinical Phase I study we require a GMP manufacturing company for the production of monoclonal antibodies (IMP) using transient and stable CHO expression systems. Bekijk de aanbesteding »
2020-03-19
Clinical Data Management and Statistics of Larissa study (CR2O B.V.)
The Larissa consortium is developing a vaccine against Rift Valley fever. CR2O is a partner within this consortium and responsible for the clinical operations. For this phase I study we require a data management and statistics service provider. Bekijk de aanbesteding »
The Larissa consortium is developing a vaccine against Rift Valley fever. CR2O is a partner within this consortium and responsible for the clinical operations. For this phase I study we require a data management and statistics service provider. Bekijk de aanbesteding »